Search results for "Skin Cream"

showing 4 items of 4 documents

Zinc(II) Complexes of Amino Acids as New Active Ingredients for Anti-Acne Dermatological Preparations.

2021

Zinc compounds have a number of beneficial properties for the skin, including antimicrobial, sebostatic and demulcent activities. The aim of the study was to develop new anti-acne preparations containing zinc–amino acid complexes as active ingredients. Firstly, the cytotoxicity of the zinc complexes was evaluated against human skin fibroblasts (1BR.3.N cell line) and human epidermal keratinocyte cell lines, and their antimicrobial activity was determined against Cutibacterium acnes. Then, zinc complexes of glycine and histidine were selected to create original gel formulations. The stability (by measuring pH, density and viscosity), microbiological purity (referring to PN-EN ISO standards) …

0301 basic medicineKeratinocytesGlycineSkin Creamchemistry.chemical_elementHuman skinZincCatalysisArticleCell LineInorganic Chemistrylcsh:Chemistry030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineantibacterial activityAcne VulgarismedicineHumansHistidinePhysical and Theoretical Chemistryzinc(II) complexesMolecular Biologylcsh:QH301-705.5acneSpectroscopyAcneHistidineSkinActive ingredientamino acidsChromatographyOrganic Chemistryskin toleranceGeneral MedicinePropionibacteriaceaeAntimicrobialmedicine.diseaseComputer Science ApplicationsAnti-Bacterial AgentsZinc030104 developmental biologychemistrylcsh:Biology (General)lcsh:QD1-999Zinc CompoundsGlycinecytotoxicityAntibacterial activityInternational journal of molecular sciences
researchProduct

Targeted Hybrid Nanocarriers as a System Enhancing the Skin Structure

2021

The skin is constantly exposed to external and internal factors that disturb its function. In this work, two nanosystems-levan nanoparticles and a surfactin-stabilized nanoemulsion were preserved (tested for microbial growth) and characterized (size, polydispersity, Zeta potential, and stability). The nanosystems were introduced in the model formulations-cream, tonic, and gel, and confirmed by TEM. The analysis showed that nanoemulsion has a spherical morphology and size 220–300 nm, while levan nanoparticles had irregular shapes independently of the use of matrix and with particle size (130–260 nm). Additionally, we examined the antiradical effect of levan nanoparticles and nanoemulsion in …

AdultskinMaterials scienceDPPHDispersitySkin CreamnanoemulsionPharmaceutical ScienceNanoparticleformulationMicrobial Sensitivity Tests02 engineering and technology030226 pharmacology & pharmacySkin DiscolorationsurfactinArticleAnalytical Chemistrylcsh:QD241-44103 medical and health scienceschemistry.chemical_compound0302 clinical medicinelcsh:Organic chemistryIn vivoDrug DiscoveryZeta potentialHumansPhysical and Theoretical ChemistryDrug CarriersBacteriaanti-agingOrganic ChemistryMiddle Aged021001 nanoscience & nanotechnologyDynamic Light ScatteringlevanFructansSkin AgingchemistryChemistry (miscellaneous)Molecular MedicineEmulsionsFemalenanoparticlesParticle sizeNanocarriers0210 nano-technologyBiomedical engineeringMolecules
researchProduct

A randomized, intraindividual, non-inferiority, Phase III study comparing daylight photodynamic therapy with BF-200 ALA gel and MAL cream for the tre…

2018

Abstract Background The most effective treatment modality for actinic keratosis (AK) is photodynamic therapy (PDT). Major obstacles of PDT are the need of a special illumination device and pain accompanying the illumination. These issues may be overcome by replacing an artificial high‐power light source with natural daylight for more extended illumination at lower light doses. Objective To determine whether BF‐200 ALA (a nanoemulsion gel containing 7.8% 5‐aminolaevulinic acid) is non‐inferior to MAL (a cream containing 16% methyl‐aminolaevulinate) in the treatment of mild‐to‐moderate AK with daylight PDT (dPDT). Non‐inferiority of the primary efficacy variable (total lesion clearance rate p…

Malemedicine.medical_specialtyKeratosisgenetic structuresOriginal Articles and Short Reports Oncologymedicine.medical_treatmentUrologySkin CreamPhotodynamic therapyDermatologyAdministration CutaneousSeverity of Illness IndexStatistics Nonparametriclaw.inventionLesion030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled triallawGermanySeverity of illnessmedicineClinical endpointHumansAgedPhotosensitizing Agentsbusiness.industryActinic keratosisAminolevulinic Acidmedicine.diseasePrognosisClinical trialKeratosis ActinicInfectious DiseasesTreatment OutcomePhotochemotherapySpain030220 oncology & carcinogenesisFemaleOriginal Articlemedicine.symptombusinessGelsJournal of the European Academy of Dermatology and Venereology : JEADV
researchProduct

A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminol…

2018

Background: Basal cell carcinoma (BCC) represents the most common nonmelanoma skin cancer worldwide, affecting mainly adult, fair-skinned individuals. The World Health Organization distinguishes aggressive and nonaggressive forms, of which prototypical variants of the latter are primary nodular and superficial BCC. Objective: To demonstrate noninferiority of BF-200 ALA (a nanoemulsion gel containing 5-aminolaevulinic acid) compared with MAL (a cream containing methyl aminolaevulinate) in the treatment of nonaggressive BCC with photodynamic therapy (PDT). Noninferiority of the primary efficacy variable (overall patient complete response 12 weeks after last PDT) would be declared if the mean …

Malemedicine.medical_specialtySkin Neoplasmsmedicine.medical_treatmentSkin CreamPhotodynamic therapyDermatologyAdministration Cutaneouslaw.invention030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled trialMethyl aminolevulinatelawCarcinomaHumansMedicineBasal cell carcinomaAgedSkinPhotosensitizing Agentsbusiness.industryActinic keratosisAminolevulinic AcidMiddle Agedmedicine.diseaseDermatologyClinical trialTreatment OutcomePhotochemotherapyCarcinoma Basal Cell030220 oncology & carcinogenesisFemaleSkin cancerbusinessmedicine.drugBritish Journal of Dermatology
researchProduct